BRPI0819765A2 - Conjugados de anticorpos anti-rg-1 - Google Patents

Conjugados de anticorpos anti-rg-1

Info

Publication number
BRPI0819765A2
BRPI0819765A2 BRPI0819765A BRPI0819765A2 BR PI0819765 A2 BRPI0819765 A2 BR PI0819765A2 BR PI0819765 A BRPI0819765 A BR PI0819765A BR PI0819765 A2 BRPI0819765 A2 BR PI0819765A2
Authority
BR
Brazil
Prior art keywords
antibody conjugates
conjugates
antibody
Prior art date
Application number
Other languages
English (en)
Inventor
David J King
Jonathan A Terrett
Sanjeev Gangwar
Josephine M Cardarelli
Chetana Raonaik
Chin Pan
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40427118&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0819765(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of BRPI0819765A2 publication Critical patent/BRPI0819765A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6869—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from a cell of the reproductive system: ovaria, uterus, testes, prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6807—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense
    • A61K47/6809—Antibiotics, e.g. antitumor antibiotics anthracyclins, adriamycin, doxorubicin or daunomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Reproductive Health (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
BRPI0819765 2007-11-30 2008-11-26 Conjugados de anticorpos anti-rg-1 BRPI0819765A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US99169007P 2007-11-30 2007-11-30
PCT/US2008/084899 WO2009073524A2 (en) 2007-11-30 2008-11-26 Conjugates of anti-rg-1 antibodies

Publications (1)

Publication Number Publication Date
BRPI0819765A2 true BRPI0819765A2 (pt) 2015-05-05

Family

ID=40427118

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0819765 BRPI0819765A2 (pt) 2007-11-30 2008-11-26 Conjugados de anticorpos anti-rg-1

Country Status (18)

Country Link
US (1) US20110020329A1 (pt)
EP (1) EP2211908A2 (pt)
JP (1) JP2011505371A (pt)
KR (1) KR20100101122A (pt)
CN (1) CN101951960A (pt)
AR (1) AR069746A1 (pt)
AU (1) AU2008331507A1 (pt)
BR (1) BRPI0819765A2 (pt)
CA (1) CA2707443A1 (pt)
CL (1) CL2008003525A1 (pt)
CO (1) CO6210734A2 (pt)
EA (1) EA201000921A1 (pt)
IL (1) IL206060A0 (pt)
MX (1) MX2010005683A (pt)
NZ (1) NZ586514A (pt)
TW (1) TW200930407A (pt)
WO (1) WO2009073524A2 (pt)
ZA (1) ZA201003729B (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA010374B1 (ru) * 2004-07-16 2008-08-29 Микромет Аг Полипептиды с повышенной экспрессией
CA2742568C (en) 2008-11-03 2017-09-26 Syntarga B.V. Novel cc-1065 analogs and their conjugates
EP3108886B1 (en) 2010-04-21 2020-06-17 Syntarga B.V. Conjugates of cc-1065 analogs and bifunctional linkers
US9714294B2 (en) 2010-05-27 2017-07-25 Genmab A/S Monoclonal antibodies against HER2 epitope
CA3051311A1 (en) 2010-05-27 2011-12-01 Genmab A/S Monoclonal antibodies against her2
US8852599B2 (en) * 2011-05-26 2014-10-07 Bristol-Myers Squibb Company Immunoconjugates, compositions for making them, and methods of making and use
TR201810856T4 (tr) 2014-01-10 2018-08-27 Synthon Biopharmaceuticals Bv CYS'le bağlı antikor-ilaç konjugatlarını saflaştırmak için usul.
CA2937561A1 (en) * 2014-01-29 2015-08-06 Shanghai Hengrui Pharmaceutical Co., Ltd. Ligand-cytotoxic drug conjugate, preparation method thereof, and uses thereof
SG11202000820PA (en) 2017-07-31 2020-02-27 Tizona Therapeutics Anti-cd39 antibodies, compositions comprising anti-cd39 antibodies and methods of using anti-cd39 antibodies

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4912227A (en) * 1984-02-21 1990-03-27 The Upjohn Company 1,2,8,8A-tetrahydrocyclopropa(c)pyrrolo(3,2-e)-indol-4-(5H)-ones and related compounds
US4978757A (en) * 1984-02-21 1990-12-18 The Upjohn Company 1,2,8,8a-tetrahydrocyclopropa (C) pyrrolo [3,2-e)]-indol-4(5H)-ones and related compounds
US5332837A (en) * 1986-12-19 1994-07-26 The Upjohn Company CC-1065 analogs
US5084468A (en) * 1988-08-11 1992-01-28 Kyowa Hakko Kogyo Co., Ltd. Dc-88a derivatives
JP2598116B2 (ja) * 1988-12-28 1997-04-09 協和醗酵工業株式会社 新規物質ｄｃ１１３
JP2510335B2 (ja) * 1989-07-03 1996-06-26 協和醗酵工業株式会社 Ｄｃ―８８ａ誘導体
US5187186A (en) * 1989-07-03 1993-02-16 Kyowa Hakko Kogyo Co., Ltd. Pyrroloindole derivatives
KR100208957B1 (ko) * 1990-04-25 1999-07-15 로렌스 티. 마이젠헬더 신규한 cc-1065 유사체
US6214345B1 (en) * 1993-05-14 2001-04-10 Bristol-Myers Squibb Co. Lysosomal enzyme-cleavable antitumor drug conjugates
US5641780A (en) * 1994-04-22 1997-06-24 Kyowa Hakko Kogyo Co., Ltd. Pyrrolo-indole derivatives
JPH07309761A (ja) * 1994-05-20 1995-11-28 Kyowa Hakko Kogyo Co Ltd デュオカルマイシン誘導体の安定化法
US5871969A (en) * 1996-02-12 1999-02-16 Human Genome Sciences, Inc. Nucleic acids encoding human neuronal attachment factor-1
US6682902B2 (en) * 1999-12-16 2004-01-27 Schering Aktiengesellschaft DNA encoding a novel RG1 polypeptide
US7129261B2 (en) * 2001-05-31 2006-10-31 Medarex, Inc. Cytotoxic agents
JP2005502703A (ja) * 2001-09-07 2005-01-27 ザ スクリプス リサーチ インスティテュート Ｃｃ−１０６５およびデュオカルマイシンのｃｂｉ類似体
US7091186B2 (en) * 2001-09-24 2006-08-15 Seattle Genetics, Inc. p-Amidobenzylethers in drug delivery agents
MXPA06000798A (es) * 2003-07-22 2006-04-07 Schering Ag Anticuerpos de rg1 y usos de los mismos.
RU2402548C2 (ru) * 2004-05-19 2010-10-27 Медарекс, Инк. Химические линкеры и их конъюгаты
WO2005112919A2 (en) * 2004-05-19 2005-12-01 Medarex, Inc. Self-immolative linkers and drug conjugates
US7714016B2 (en) * 2005-04-08 2010-05-11 Medarex, Inc. Cytotoxic compounds and conjugates with cleavable substrates
EP1940470B1 (en) * 2005-09-26 2013-04-17 Medarex, Inc. Antibody-drug conjugates and their use
CA2627190A1 (en) * 2005-11-10 2007-05-24 Medarex, Inc. Duocarmycin derivatives as novel cytotoxic compounds and conjugates
EP2799449A1 (en) * 2006-05-25 2014-11-05 Bayer Intellectual Property GmbH Dimeric molecular complexes

Also Published As

Publication number Publication date
CO6210734A2 (es) 2010-10-20
JP2011505371A (ja) 2011-02-24
WO2009073524A3 (en) 2009-12-10
EP2211908A2 (en) 2010-08-04
AR069746A1 (es) 2010-02-17
AU2008331507A1 (en) 2009-06-11
WO2009073524A2 (en) 2009-06-11
CN101951960A (zh) 2011-01-19
MX2010005683A (es) 2010-06-11
TW200930407A (en) 2009-07-16
KR20100101122A (ko) 2010-09-16
CA2707443A1 (en) 2009-06-11
EA201000921A1 (ru) 2010-12-30
CL2008003525A1 (es) 2010-01-22
US20110020329A1 (en) 2011-01-27
NZ586514A (en) 2012-05-25
IL206060A0 (en) 2010-11-30
ZA201003729B (en) 2011-08-31

Similar Documents

Publication Publication Date Title
CY2021027I2 (el) Σκευασματα αντισωματων anti-cd20
CY2019004I1 (el) Τροποποιημενα αντισωματα αντι-ιl-23ρ19
BRPI0814252A2 (pt) Formulações de anticorpo
BRPI0820819A2 (pt) Formulação de anticorpos
BRPI0907237A2 (pt) Anticorpo anti-cldn6
HRP20171011T1 (hr) ANTI-eMET ANTITIJELO
EP2211903A4 (en) CLL-1 ANTIBODY
PL3059246T3 (pl) Zmodyfikowany region stały przeciwciała
PT2180901E (pt) Purificação de conjugados utilizando hidroxiapatite
DK1912671T3 (da) Beta-glucuronid-linker-lægemiddelkonjugater
HUE056626T2 (hu) Antitestkészítmény
DK2066695T3 (da) Anti-myostatin-antistoffer
BRPI0906877A2 (pt) Anticorpos anti-trkb aperfeiçoados
IL212175B (en) Muc1* antibodies
EP2172483A4 (en) ANTI-MUC17 ANTIBODY
BRPI0807991A2 (pt) Anticorpos anti-il-23r elaborados.
EP2337798A4 (en) SPECIFIC ANTIBODIES OF THE ASB
BRPI0817427A2 (pt) Anticorpo anti-bst2
BRPI0923047A2 (pt) "conjugados de proteínas-oligossacarídeos".
BRPI0815567A2 (pt) Anticorpos híbridos antialfa v-integrina projetados
BRPI0814111A2 (pt) Anticorpo monoclonal citotóxico anticâncer
BRPI0909633A2 (pt) anticorpos anti-tyrp1
EP2212431A4 (en) ANTIBODY AGAINST IREM-1
BRPI0819765A2 (pt) Conjugados de anticorpos anti-rg-1
FR22C1045I2 (fr) Conjugués protéine-polymère

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 5A E 6A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2329 DE 25-08-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.

B15K Others concerning applications: alteration of classification

Ipc: A61K 47/68 (2017.01), A61P 35/00 (2006.01)